Skip to content

Retrospective cohort study of Feduqing in the treatment of severe COVID-19

Retrospective cohort study of Feduqing in the treatment of severe COVID-19

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067952
Enrollment
Unknown
Registered
2023-02-01
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Group A:Western medicine basic treatment + Feduqing
Group B:Western medicine basic treatment

Sponsors

Jiujiang Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: In accordance with the National Health Commission issued the "Novel Coronavirus Pneumonia diagnosis and Treatment Protocol (10th edition)" on the diagnosis of severe COVID-19, with clinical manifestations of novel coronavirus infection; Positive for COVID-19 nucleic acid test, positive for antigen test, positive for isolation and culture of COVID-19, or the level of virus-specific IgG antibody in the recovery phase is four times or more than that in the acute phase. And meet any of the following criteria: shortness of breath, RR>= 30 times/min; In the resting state, oxygen saturation of finger is less than 93% when sucking air; Arterial partial oxygen pressure (PaO2)/ oxygen absorption concentration (FiO2) 50% within 24-48 hours.

Exclusion criteria

Exclusion criteria: Asymptomatic, mild or medium-sized infected persons; Pregnant or lactating women; People who are allergic to the drugs in "Feiduqing" and allergic to the constitution; Patients with serious underlying diseases such as malignant tumor, cirrhosis, chronic renal failure (uremic stage), blood system diseases, HIV, etc.; Pulmonary neoplasms caused obstructive pneumonia, pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis; Long-term use of hormones, immunosuppressive drugs; Severe mental illness or inability to cooperate with researchers

Design outcomes

Primary

MeasureTime frame
CT Scan of the Lungs;

Secondary

MeasureTime frame
TNF-a;IL-6;IL-10;CRP;procalcitonin;myocardial enzyme;liver function;renal function;coagulation function;

Countries

China

Contacts

Public ContactHongze Wu

Jiujiang Hospital of Traditional Chinese Medicine

yihuihn@163.com+86 18970256865

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026